34 research outputs found
Π ΠΎΠ·ΡΠΎΠ±ΠΊΠ° ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΡΡ ΡΡΠΈΠ»ΡΠ·Π°ΡΡΡ ΠΏΡΠΎΠ΄ΡΠΊΡΡΠ² ΠΎΡΠΈΡΡΠΊΠΈ ΠΏΡΠΎΠΌΠΈΡΠ»ΠΎΠ²ΠΈΡ ΡΡΠΎΠΊΡΠ² ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΡΠ΅ΡΠΈΡΠΈΠ·Π°ΡΡΡ Ρ ΠΌΠ°ΡΡΠΈΡΡ Π»ΡΠΆΠ½ΠΈΡ ΡΠ΅ΠΌΠ΅Π½ΡΡΠ²
The object of research is liquid and solid wastes resulting from the processing of highly concentrated wastewater from industrial enterprises using the ferritization method. It is known that galvanic production creates large volumes of highly toxic waste requiring further processing or safe disposal. One of the most problematic places is the use of traditional reagent methods that do not provide high rates of treated water and chemical stability of a significant amount of solid-phase waste water.The use of ferritization technology allows eliminating the indicated disadvantages and increasing the efficiency of the industrial wastewater treatment process. In the course of the study, improved ferritization method with electromagnetic activation of the process is used, which can significantly increase its energy efficiency. However, dense and stable ferritization sediments that contain toxic compounds of heavy metals need reliable disposal. But even with proper treatment of wastewater from heavy metal compounds, they contain a large amount of other pollutants, making it impossible to discharge such water into natural water bodies, in particular, because of its increased alkalinity. Environmentally safe use of such substandard products in solid and liquid state as components of building materials is developed. The most effective cementing materials with reliable immobilization of industrial waste compounds are alkaline binders. The performance properties of such modified alkaline cements and concretes based on them are obtained. The leaching of heavy metal ions from the matrix of the material is investigated and their reliable fixation in the structure of alkaline cements is proved. Due to this, immobilization of water treatment products in alkaline cements and concretes based on them does not degrade the performance of their properties and at the same time provides the advantages of such waste disposal.Compared with similar known technologies, a completely waste-free complex treatment of industrial wastes of electroplating plants of industrial enterprises is developed.ΠΠ±ΡΠ΅ΠΊΡΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΡΠ²Π»ΡΡΡΡΡ ΠΆΠΈΠ΄ΠΊΠΈΠ΅ ΠΈ ΡΠ²Π΅ΡΠ΄ΡΠ΅ ΠΎΡΡ
ΠΎΠ΄Ρ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΏΠΎΠ»ΡΡΠ΅Π½Ρ Π² ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ ΠΏΠ΅ΡΠ΅ΡΠ°Π±ΠΎΡΠΊΠΈ Π²ΡΡΠΎΠΊΠΎΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΡΡΠΎΡΠ½ΡΡ
Π²ΠΎΠ΄ ΠΏΡΠΎΠΌΡΡΠ»Π΅Π½Π½ΡΡ
ΠΏΡΠ΅Π΄ΠΏΡΠΈΡΡΠΈΠΉ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΡΠ΅ΡΡΠΈΡΠΈΠ·Π°ΡΠΈΠΈ. ΠΠ·Π²Π΅ΡΡΠ½ΠΎ, ΡΡΠΎ Π³Π°Π»ΡΠ²Π°Π½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π° ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡ Π±ΠΎΠ»ΡΡΠΈΠ΅ ΠΎΠ±ΡΠ΅ΠΌΡ Π²ΡΡΠΎΠΊΠΎΡΠΎΠΊΡΠΈΡΠ½ΡΡ
ΠΎΡΡ
ΠΎΠ΄ΠΎΠ², ΠΊΠΎΡΠΎΡΡΠ΅ ΡΡΠ΅Π±ΡΡΡ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅ΠΉ ΠΏΠ΅ΡΠ΅ΡΠ°Π±ΠΎΡΠΊΠΈ ΠΈΠ»ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΠ³ΠΎ Π·Π°Ρ
ΠΎΡΠΎΠ½Π΅Π½ΠΈΡ. ΠΠ΄Π½ΠΈΠΌ ΠΈΠ· Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ½ΡΡ
ΠΌΠ΅ΡΡ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΡΡ
ΡΠ΅Π°Π³Π΅Π½ΡΠ½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ², ΠΊΠΎΡΠΎΡΡΠ΅ Π½Π΅ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°ΡΡ Π²ΡΡΠΎΠΊΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΎΡΠΈΡΠ΅Π½Π½ΠΎΠΉ Π²ΠΎΠ΄Ρ ΠΈ Ρ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠΎΠΉΠΊΠΎΡΡΠΈ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° ΡΠ²Π΅ΡΠ΄ΠΎΡΠ°Π·ΠΎΠ²ΡΡ
ΠΎΡΡ
ΠΎΠ΄ΠΎΠ² Π²ΠΎΠ΄ΠΎΠΎΡΠΈΡΡΠΊΠΈ.ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ΅ΡΡΠΈΡΠΈΠ·Π°ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΈΠ·Π±Π΅ΠΆΠ°ΡΡ ΡΠΊΠ°Π·Π°Π½Π½ΡΡ
Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΊΠΎΠ² ΠΈ ΡΠ»ΡΡΡΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΡΠΎΡΠ΅ΡΡΠ° ΠΏΠ΅ΡΠ΅ΡΠ°Π±ΠΎΡΠΊΠΈ ΡΡΠΎΡΠ½ΡΡ
Π²ΠΎΠ΄. Π Ρ
ΠΎΠ΄Π΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΡΡΠΎΠ²Π΅ΡΡΠ΅Π½ΡΡΠ²ΠΎΠ²Π°Π½Π½ΡΠΉ Π°Π²ΡΠΎΡΠ°ΠΌΠΈ ΠΌΠ΅ΡΠΎΠ΄ ΡΠ΅ΡΡΠΈΡΠΈΠ·Π°ΡΠΈΠΈ Ρ ΡΠ»Π΅ΠΊΡΡΠΎΠΌΠ°Π³Π½ΠΈΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠ΅ΠΉ ΠΏΡΠΎΡΠ΅ΡΡΠ°, ΠΊΠΎΡΠΎΡΡΠΉ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΠΏΠΎΠ²ΡΡΠΈΡΡ Π΅Π³ΠΎ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ. ΠΠ΄Π½Π°ΠΊΠΎ ΠΏΠ»ΠΎΡΠ½ΡΠ΅ ΠΈ ΡΡΠΎΠΉΠΊΠΈΠ΅ ΠΎΡΠ°Π΄ΠΊΠΈ ΡΠ΅ΡΡΠΈΡΠΈΠ·Π°ΡΠΈΠΈ, ΠΊΠΎΡΠΎΡΡΠ΅ ΡΠΎΠ΄Π΅ΡΠΆΠ°Ρ ΡΠΎΠΊΡΠΈΡΠ½ΡΠ΅ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΡ ΡΡΠΆΠ΅Π»ΡΡ
ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠ², ΡΡΠ΅Π±ΡΡΡ Π½Π°Π΄Π΅ΠΆΠ½ΠΎΠΉ ΡΡΠΈΠ»ΠΈΠ·Π°ΡΠΈΠΈ. ΠΠΎ Π΄Π°ΠΆΠ΅ ΠΏΡΠΈ Π½Π°Π΄Π»Π΅ΠΆΠ°ΡΠ΅ΠΉ ΠΎΡΠΈΡΡΠΊΠ΅ ΡΡΠΎΡΠ½ΡΡ
Π²ΠΎΠ΄ ΠΎΡ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ ΡΡΠΆΠ΅Π»ΡΡ
ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠ² ΠΎΠ½ΠΈ ΡΠΎΠ΄Π΅ΡΠΆΠ°Ρ Π±ΠΎΠ»ΡΡΠΎΠ΅ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ Π΄ΡΡΠ³ΠΈΡ
Π·Π°Π³ΡΡΠ·Π½ΠΈΡΠ΅Π»Π΅ΠΉ, ΡΡΠΎ Π΄Π΅Π»Π°Π΅Ρ Π½Π΅Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΡΠΌ ΡΠ±ΡΠΎΡ ΡΠ°ΠΊΠΎΠΉ Π²ΠΎΠ΄Ρ Π² ΠΏΡΠΈΡΠΎΠ΄Π½ΡΠ΅ Π²ΠΎΠ΄ΠΎΠ΅ΠΌΡ, Π² ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ, Π²Π²ΠΈΠ΄Ρ Π΅Π΅ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΠΎΠΉ ΡΠ΅Π»ΠΎΡΠ½ΠΎΡΡΠΈ. Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° ΡΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½Π°Ρ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΡΠ°ΠΊΠΈΡ
Π½Π΅ΠΊΠΎΠ½Π΄ΠΈΡΠΈΠΎΠ½Π½ΡΡ
ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ² Π² ΡΠ²Π΅ΡΠ΄ΠΎΠΌ ΠΈ ΠΆΠΈΠ΄ΠΊΠΎΠΌ ΡΠΎΡΡΠΎΡΠ½ΠΈΠΈ ΠΊΠ°ΠΊ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠ² ΡΡΡΠΎΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ². ΠΠ°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌΠΈ ΡΠ΅ΠΌΠ΅Π½ΡΠΈΡΡΡΡΠΈΠΌΠΈ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π°ΠΌΠΈ Ρ Π½Π°Π΄Π΅ΠΆΠ½ΠΎΠΉ ΠΈΠΌΠΌΠΎΠ±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΠ΅ΠΉ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ ΡΡΠΆΠ΅Π»ΡΡ
ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠ² ΡΠ²Π»ΡΡΡΡΡ ΡΠ΅Π»ΠΎΡΠ½ΡΠ΅ Π²ΡΠΆΡΡΠΈΠ΅ Π²Π΅ΡΠ΅ΡΡΠ²Π°. Π ΡΠ°Π±ΠΎΡΠ΅ ΠΏΠΎΠ»ΡΡΠ΅Π½Ρ ΡΠΊΡΠΏΠ»ΡΠ°ΡΠ°ΡΠΈΠΎΠ½Π½ΡΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° ΡΠ°ΠΊΠΈΡ
ΠΌΠΎΠ΄ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΡΠ΅Π»ΠΎΡΠ½ΡΡ
ΡΠ΅ΠΌΠ΅Π½ΡΠΎΠ² ΠΈ Π±Π΅ΡΠΎΠ½ΠΎΠ² Π½Π° ΠΈΡ
ΠΎΡΠ½ΠΎΠ²Π΅. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΎ Π²ΡΡΠ΅Π»Π°ΡΠΈΠ²Π°Π½ΠΈΠ΅ ΠΈΠΎΠ½ΠΎΠ² ΡΡΠΆΠ΅Π»ΡΡ
ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠ² ΠΈΠ· ΠΌΠ°ΡΡΠΈΡΡ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π° ΠΈ Π΄ΠΎΠΊΠ°Π·Π°Π½Π° ΠΈΡ
Π½Π°Π΄Π΅ΠΆΠ½Π°Ρ ΡΠΈΠΊΡΠ°ΡΠΈΡ Π² ΡΡΡΡΠΊΡΡΡΠ΅ ΡΠ΅Π»ΠΎΡΠ½ΡΡ
ΡΠ΅ΠΌΠ΅Π½ΡΠΎΠ². ΠΠ»Π°Π³ΠΎΠ΄Π°ΡΡ ΡΡΠΎΠΌΡ ΠΈΠΌΠΌΠΎΠ±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΡ ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ² Π²ΠΎΠ΄ΠΎΠΎΡΠΈΡΡΠΊΠΈ Π² ΡΠ΅Π»ΠΎΡΠ½ΡΡ
ΡΠ΅ΠΌΠ΅Π½ΡΠ°Ρ
ΠΈ Π±Π΅ΡΠΎΠ½Π°Ρ
Π½Π° ΠΈΡ
ΠΎΡΠ½ΠΎΠ²Π΅ Π½Π΅ ΡΡ
ΡΠ΄ΡΠ°Π΅Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΈΡ
ΡΠΊΡΠΏΠ»ΡΠ°ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΡΠ²ΠΎΠΉΡΡΠ² ΠΈ ΠΏΡΠΈ ΡΡΠΎΠΌ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°Π΅Ρ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π° ΡΠ°ΠΊΠΎΠΉ ΡΡΠΈΠ»ΠΈΠ·Π°ΡΠΈΠΈ ΠΎΡΡ
ΠΎΠ΄ΠΎΠ².Π ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ Π°Π½Π°Π»ΠΎΠ³ΠΈΡΠ½ΡΠΌΠΈ ΠΈΠ·Π²Π΅ΡΡΠ½ΡΠΌΠΈ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠΌΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° ΠΏΠΎΠ»Π½ΠΎΡΡΡΡ Π±Π΅Π·ΠΎΡΡ
ΠΎΠ΄Π½Π°Ρ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΠΎΡΠΈΡΡΠΊΠΈ ΠΏΡΠΎΠΌΡΡΠ»Π΅Π½Π½ΡΡ
ΡΡΠΎΠΊΠΎΠ² Π³Π°Π»ΡΠ²Π°Π½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ² ΠΏΡΠΎΠΌΡΡΠ»Π΅Π½Π½ΡΡ
ΠΏΡΠ΅Π΄ΠΏΡΠΈΡΡΠΈΠΉ.ΠΠ±'ΡΠΊΡΠΎΠΌ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Ρ ΡΡΠ΄ΠΊΡ ΡΠ° ΡΠ²Π΅ΡΠ΄Ρ Π²ΡΠ΄Ρ
ΠΎΠ΄ΠΈ, ΡΠΊΡ ΠΎΡΡΠΈΠΌΠ°Π½Ρ Π² ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΠ΅ΡΠ΅ΡΠΎΠ±ΠΊΠΈ Π²ΠΈΡΠΎΠΊΠΎΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠΎΠ²Π°Π½ΠΈΡ
ΡΡΡΡΠ½ΠΈΡ
Π²ΠΎΠ΄ ΠΏΡΠΎΠΌΠΈΡΠ»ΠΎΠ²ΠΈΡ
ΠΏΡΠ΄ΠΏΡΠΈΡΠΌΡΡΠ² ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΡΠ΅ΡΠΈΡΠΈΠ·Π°ΡΡΡ. ΠΡΠ΄ΠΎΠΌΠΎ, ΡΠΎ Π³Π°Π»ΡΠ²Π°Π½ΡΡΠ½Ρ Π²ΠΈΡΠΎΠ±Π½ΠΈΡΡΠ²Π° ΡΡΠ²ΠΎΡΡΡΡΡ Π²Π΅Π»ΠΈΠΊΡ ΠΎΠ±βΡΠΌΠΈ Π²ΠΈΡΠΎΠΊΠΎΡΠΎΠΊΡΠΈΡΠ½ΠΈΡ
Π²ΡΠ΄Ρ
ΠΎΠ΄ΡΠ², ΡΠΊΡ ΠΏΠΎΡΡΠ΅Π±ΡΡΡΡ ΠΏΠΎΠ΄Π°Π»ΡΡΠΎΡ ΠΏΠ΅ΡΠ΅ΡΠΎΠ±ΠΊΠΈ Π°Π±ΠΎ Π±Π΅Π·ΠΏΠ΅ΡΠ½ΠΎΠ³ΠΎ Π·Π°Ρ
ΠΎΡΠΎΠ½Π΅Π½Π½Ρ. ΠΠ΄Π½ΠΈΠΌ Π· Π½Π°ΠΉΠ±ΡΠ»ΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ½ΠΈΡ
ΠΌΡΡΡΡ Ρ Π·Π°ΡΡΠΎΡΡΠ²Π°Π½Π½Ρ ΡΡΠ°Π΄ΠΈΡΡΠΉΠ½ΠΈΡ
ΡΠ΅Π°Π³Π΅Π½ΡΠ½ΠΈΡ
ΠΌΠ΅ΡΠΎΠ΄ΡΠ², ΡΠΊΡ Π½Π΅ Π·Π°Π±Π΅Π·ΠΏΠ΅ΡΡΡΡΡ Π²ΠΈΡΠΎΠΊΠΈΡ
ΠΏΠΎΠΊΠ°Π·Π½ΠΈΠΊΡΠ² ΠΎΡΠΈΡΠ΅Π½ΠΎΡ Π²ΠΎΠ΄ΠΈ ΡΠ° Ρ
ΡΠΌΡΡΠ½ΠΎΡ ΡΡΡΠΉΠΊΠΎΡΡΡ Π·Π½Π°ΡΠ½ΠΎΡ ΠΊΡΠ»ΡΠΊΠΎΡΡΡ ΡΠ²Π΅ΡΠ΄ΠΎΡΠ°Π·Π½ΠΈΡ
Π²ΡΠ΄Ρ
ΠΎΠ΄ΡΠ² Π²ΠΎΠ΄ΠΎΠΎΡΠΈΡΠ΅Π½Π½Ρ.ΠΠΈΠΊΠΎΡΠΈΡΡΠ°Π½Π½Ρ ΡΠ΅ΡΠΈΡΠΈΠ·Π°ΡΡΠΉΠ½ΠΎΡ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΡΡ Π΄ΠΎΠ·Π²ΠΎΠ»ΡΡ ΡΡΡΠ½ΡΡΠΈ Π·Π°Π·Π½Π°ΡΠ΅Π½Ρ Π½Π΅Π΄ΠΎΠ»ΡΠΊΠΈ ΡΠ° ΠΏΠΎΠΊΡΠ°ΡΠΈΡΠΈ Π΅ΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡΡΡ ΠΏΡΠΎΡΠ΅ΡΡ ΠΏΠ΅ΡΠ΅ΡΠΎΠ±ΠΊΠΈ ΠΏΡΠΎΠΌΠΈΡΠ»ΠΎΠ²ΠΈΡ
ΡΡΡΡΠ½ΠΈΡ
Π²ΠΎΠ΄. Π Ρ
ΠΎΠ΄Ρ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π²ΠΈΠΊΠΎΡΠΈΡΡΠΎΠ²ΡΠ²Π°Π»ΠΈΡΡ ΡΠ΄ΠΎΡΠΊΠΎΠ½Π°Π»Π΅Π½ΠΈΠΉ Π°Π²ΡΠΎΡΠ°ΠΌΠΈ ΠΌΠ΅ΡΠΎΠ΄ ΡΠ΅ΡΠΈΡΠΈΠ·Π°ΡΡΡ ΡΠ· Π΅Π»Π΅ΠΊΡΡΠΎΠΌΠ°Π³Π½ΡΡΠ½ΠΎΡ Π°ΠΊΡΠΈΠ²Π°ΡΡΡΡ ΠΏΡΠΎΡΠ΅ΡΡ, ΡΠΎ Π΄ΠΎΠ·Π²ΠΎΠ»ΡΡ ΡΡΡΡΡΠ²ΠΎ ΠΏΡΠ΄Π²ΠΈΡΠΈΡΠΈ ΠΉΠΎΠ³ΠΎ Π΅Π½Π΅ΡΠ³ΠΎΠ΅ΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡΡΡ. ΠΡΠΎΡΠ΅ ΡΡΠ»ΡΠ½Ρ Ρ ΡΡΡΠΉΠΊΡ ΠΎΡΠ°Π΄ΠΈ ΡΠ΅ΡΠΈΡΠΈΠ·Π°ΡΡΡ, ΡΠΊΡ ΠΌΡΡΡΡΡΡ ΡΠΎΠΊΡΠΈΡΠ½Ρ ΡΠΏΠΎΠ»ΡΠΊΠΈ Π²Π°ΠΆΠΊΠΈΡ
ΠΌΠ΅ΡΠ°Π»ΡΠ², ΠΏΠΎΡΡΠ΅Π±ΡΡΡΡ Π½Π°Π΄ΡΠΉΠ½ΠΎΡ ΡΡΠΈΠ»ΡΠ·Π°ΡΡΡ. ΠΠ»Π΅ Π½Π°Π²ΡΡΡ ΠΏΡΠΈ Π½Π°Π»Π΅ΠΆΠ½ΠΎΠΌΡ ΠΎΡΠΈΡΠ΅Π½Π½Ρ ΡΡΡΡΠ½ΠΈΡ
Π²ΠΎΠ΄ Π²ΡΠ΄ ΡΠΏΠΎΠ»ΡΠΊ Π²Π°ΠΆΠΊΠΈΡ
ΠΌΠ΅ΡΠ°Π»ΡΠ², Π²ΠΎΠ½ΠΈ ΠΌΡΡΡΡΡΡ Π²Π΅Π»ΠΈΠΊΡ ΠΊΡΠ»ΡΠΊΡΡΡΡ ΡΠ½ΡΠΈΡ
Π·Π°Π±ΡΡΠ΄Π½ΡΠ²Π°ΡΡΠ², ΡΠΎ ΡΠ½Π΅ΠΌΠΎΠΆΠ»ΠΈΠ²Π»ΡΡ ΡΠΊΠΈΠ΄Π°Π½Π½Ρ ΡΠ°ΠΊΠΎΡ Π²ΠΎΠ΄ΠΈ Ρ ΠΏΡΠΈΡΠΎΠ΄Π½Ρ Π²ΠΎΠ΄ΠΎΠΉΠΌΠΈ, Π·ΠΎΠΊΡΠ΅ΠΌΠ°, ΡΠ΅ΡΠ΅Π· ΡΡ ΠΏΡΠ΄Π²ΠΈΡΠ΅Π½Ρ Π»ΡΠΆΠ½ΡΡΡΡ. Π ΠΎΠ·ΡΠΎΠ±Π»Π΅Π½ΠΎ Π΅ΠΊΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΎ Π±Π΅Π·ΠΏΠ΅ΡΠ½Π΅ Π²ΠΈΠΊΠΎΡΠΈΡΡΠ°Π½Π½Ρ ΡΠ°ΠΊΠΈΡ
Π½Π΅ΠΊΠΎΠ½Π΄ΠΈΡΡΠΉΠ½ΠΈΡ
ΠΏΡΠΎΠ΄ΡΠΊΡΡΠ² Ρ ΡΠ²Π΅ΡΠ΄ΠΎΠΌΡ ΡΠ° ΡΡΠ΄ΠΊΠΎΠΌΡ ΡΡΠ°Π½Ρ ΡΠΊ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΡΠ² Π±ΡΠ΄ΡΠ²Π΅Π»ΡΠ½ΠΈΡ
ΠΌΠ°ΡΠ΅ΡΡΠ°Π»ΡΠ². ΠΠ°ΠΉΠ±ΡΠ»ΡΡ Π΅ΡΠ΅ΠΊΡΠΈΠ²Π½ΠΈΠΌΠΈ ΡΠ΅ΠΌΠ΅Π½ΡΡΡΡΠΈΠΌΠΈ ΠΌΠ°ΡΠ΅ΡΡΠ°Π»Π°ΠΌΠΈ ΡΠ· Π½Π°Π΄ΡΠΉΠ½ΠΎΡ ΡΠΌΠΌΠΎΠ±ΡΠ»ΡΠ·Π°ΡΡΡ ΡΠΏΠΎΠ»ΡΠΊ ΠΏΡΠΎΠΌΠΈΡΠ»ΠΎΠ²ΠΈΡ
Π²ΡΠ΄Ρ
ΠΎΠ΄ΡΠ² Ρ Π»ΡΠΆΠ½Ρ Π²βΡΠΆΡΡΡ ΡΠ΅ΡΠΎΠ²ΠΈΠ½ΠΈ. Π ΡΠΎΠ±ΠΎΡΡ ΠΎΡΡΠΈΠΌΠ°Π½Ρ Π΅ΠΊΡΠΏΠ»ΡΠ°ΡΠ°ΡΡΠΉΠ½Ρ Π²Π»Π°ΡΡΠΈΠ²ΠΎΡΡΡ ΡΠ°ΠΊΠΈΡ
ΠΌΠΎΠ΄ΠΈΡΡΠΊΠΎΠ²Π°Π½ΠΈΡ
Π»ΡΠΆΠ½ΠΈΡ
ΡΠ΅ΠΌΠ΅Π½ΡΡΠ² ΡΠ° Π±Π΅ΡΠΎΠ½ΡΠ² Π½Π° ΡΡ
ΠΎΡΠ½ΠΎΠ²Ρ. ΠΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½ΠΎ Π²ΠΈΠ»ΡΠ³ΠΎΠ²ΡΠ²Π°Π½Π½Ρ ΡΠΎΠ½ΡΠ² Π²Π°ΠΆΠΊΠΈΡ
ΠΌΠ΅ΡΠ°Π»ΡΠ² ΡΠ· ΠΌΠ°ΡΡΠΈΡΡ ΠΌΠ°ΡΠ΅ΡΡΠ°Π»Ρ ΡΠ° Π΄ΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΡΡ
Π½Π°Π΄ΡΠΉΠ½Ρ ΡΡΠΊΡΠ°ΡΡΡ Ρ ΡΡΡΡΠΊΡΡΡΡ Π»ΡΠΆΠ½ΠΈΡ
ΡΠ΅ΠΌΠ΅Π½ΡΡΠ². ΠΠ°Π²Π΄ΡΠΊΠΈ ΡΡΠΎΠΌΡ ΡΠΌΠΌΠΎΠ±ΡΠ»ΡΠ·Π°ΡΡΡ ΠΏΡΠΎΠ΄ΡΠΊΡΡΠ² Π²ΠΎΠ΄ΠΎΠΎΡΠΈΡΠ΅Π½Π½Ρ Π² Π»ΡΠΆΠ½ΠΈΡ
ΡΠ΅ΠΌΠ΅Π½ΡΠ°Ρ
ΡΠ° Π±Π΅ΡΠΎΠ½Π°Ρ
Π½Π° ΡΡ
ΠΎΡΠ½ΠΎΠ²Ρ Π½Π΅ ΠΏΠΎΠ³ΡΡΡΡΡ ΠΏΠΎΠΊΠ°Π·Π½ΠΈΠΊΠΈ ΡΡ
Π΅ΠΊΡΠΏΠ»ΡΠ°ΡΠ°ΡΡΠΉΠ½ΠΈΡ
Π²Π»Π°ΡΡΠΈΠ²ΠΎΡΡΠ΅ΠΉ Ρ ΠΏΡΠΈ ΡΡΠΎΠΌΡ Π·Π°Π±Π΅Π·ΠΏΠ΅ΡΡΡ ΠΏΠ΅ΡΠ΅Π²Π°Π³ΠΈ ΡΠ°ΠΊΠΎΡ ΡΡΠΈΠ»ΡΠ·Π°ΡΡΡ Π²ΡΠ΄Ρ
ΠΎΠ΄ΡΠ².Π£ ΠΏΠΎΡΡΠ²Π½ΡΠ½Π½Ρ Π· Π°Π½Π°Π»ΠΎΠ³ΡΡΠ½ΠΈΠΌΠΈ Π²ΡΠ΄ΠΎΠΌΠΈΠΌΠΈ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΡΡΠΌΠΈ ΡΠΎΠ·ΡΠΎΠ±Π»Π΅Π½ΠΎ ΠΏΠΎΠ²Π½ΡΡΡΡ Π±Π΅Π·Π²ΡΠ΄Ρ
ΠΎΠ΄Π½Ρ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½Ρ ΠΎΡΠΈΡΡΠΊΡ ΠΏΡΠΎΠΌΠΈΡΠ»ΠΎΠ²ΠΈΡ
ΡΡΠΎΠΊΡΠ² Π³Π°Π»ΡΠ²Π°Π½ΡΡΠ½ΠΈΡ
Π²ΠΈΡΠΎΠ±Π½ΠΈΡΡΠ² ΠΏΡΠΎΠΌΠΈΡΠ»ΠΎΠ²ΠΈΡ
ΠΏΡΠ΄ΠΏΡΠΈΡΠΌΡΡΠ²
Π ΠΎΠ·ΡΠΎΠ±ΠΊΠ° ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΡΡ ΡΡΠΈΠ»ΡΠ·Π°ΡΡΡ ΠΏΡΠΎΠ΄ΡΠΊΡΡΠ² ΠΎΡΠΈΡΡΠΊΠΈ ΠΏΡΠΎΠΌΠΈΡΠ»ΠΎΠ²ΠΈΡ ΡΡΠΎΠΊΡΠ² ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΡΠ΅ΡΠΈΡΠΈΠ·Π°ΡΡΡ Ρ ΠΌΠ°ΡΡΠΈΡΡ Π»ΡΠΆΠ½ΠΈΡ ΡΠ΅ΠΌΠ΅Π½ΡΡΠ²
The object of research is liquid and solid wastes resulting from the processing of highly concentrated wastewater from industrial enterprises using the ferritization method. It is known that galvanic production creates large volumes of highly toxic waste requiring further processing or safe disposal. One of the most problematic places is the use of traditional reagent methods that do not provide high rates of treated water and chemical stability of a significant amount of solid-phase waste water.The use of ferritization technology allows eliminating the indicated disadvantages and increasing the efficiency of the industrial wastewater treatment process. In the course of the study, improved ferritization method with electromagnetic activation of the process is used, which can significantly increase its energy efficiency. However, dense and stable ferritization sediments that contain toxic compounds of heavy metals need reliable disposal. But even with proper treatment of wastewater from heavy metal compounds, they contain a large amount of other pollutants, making it impossible to discharge such water into natural water bodies, in particular, because of its increased alkalinity. Environmentally safe use of such substandard products in solid and liquid state as components of building materials is developed. The most effective cementing materials with reliable immobilization of industrial waste compounds are alkaline binders. The performance properties of such modified alkaline cements and concretes based on them are obtained. The leaching of heavy metal ions from the matrix of the material is investigated and their reliable fixation in the structure of alkaline cements is proved. Due to this, immobilization of water treatment products in alkaline cements and concretes based on them does not degrade the performance of their properties and at the same time provides the advantages of such waste disposal.Compared with similar known technologies, a completely waste-free complex treatment of industrial wastes of electroplating plants of industrial enterprises is developed.ΠΠ±ΡΠ΅ΠΊΡΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΡΠ²Π»ΡΡΡΡΡ ΠΆΠΈΠ΄ΠΊΠΈΠ΅ ΠΈ ΡΠ²Π΅ΡΠ΄ΡΠ΅ ΠΎΡΡ
ΠΎΠ΄Ρ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΏΠΎΠ»ΡΡΠ΅Π½Ρ Π² ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ ΠΏΠ΅ΡΠ΅ΡΠ°Π±ΠΎΡΠΊΠΈ Π²ΡΡΠΎΠΊΠΎΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΡΡΠΎΡΠ½ΡΡ
Π²ΠΎΠ΄ ΠΏΡΠΎΠΌΡΡΠ»Π΅Π½Π½ΡΡ
ΠΏΡΠ΅Π΄ΠΏΡΠΈΡΡΠΈΠΉ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΡΠ΅ΡΡΠΈΡΠΈΠ·Π°ΡΠΈΠΈ. ΠΠ·Π²Π΅ΡΡΠ½ΠΎ, ΡΡΠΎ Π³Π°Π»ΡΠ²Π°Π½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π° ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡ Π±ΠΎΠ»ΡΡΠΈΠ΅ ΠΎΠ±ΡΠ΅ΠΌΡ Π²ΡΡΠΎΠΊΠΎΡΠΎΠΊΡΠΈΡΠ½ΡΡ
ΠΎΡΡ
ΠΎΠ΄ΠΎΠ², ΠΊΠΎΡΠΎΡΡΠ΅ ΡΡΠ΅Π±ΡΡΡ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅ΠΉ ΠΏΠ΅ΡΠ΅ΡΠ°Π±ΠΎΡΠΊΠΈ ΠΈΠ»ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΠ³ΠΎ Π·Π°Ρ
ΠΎΡΠΎΠ½Π΅Π½ΠΈΡ. ΠΠ΄Π½ΠΈΠΌ ΠΈΠ· Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ½ΡΡ
ΠΌΠ΅ΡΡ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΡΡ
ΡΠ΅Π°Π³Π΅Π½ΡΠ½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ², ΠΊΠΎΡΠΎΡΡΠ΅ Π½Π΅ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°ΡΡ Π²ΡΡΠΎΠΊΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΎΡΠΈΡΠ΅Π½Π½ΠΎΠΉ Π²ΠΎΠ΄Ρ ΠΈ Ρ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠΎΠΉΠΊΠΎΡΡΠΈ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° ΡΠ²Π΅ΡΠ΄ΠΎΡΠ°Π·ΠΎΠ²ΡΡ
ΠΎΡΡ
ΠΎΠ΄ΠΎΠ² Π²ΠΎΠ΄ΠΎΠΎΡΠΈΡΡΠΊΠΈ.ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ΅ΡΡΠΈΡΠΈΠ·Π°ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΈΠ·Π±Π΅ΠΆΠ°ΡΡ ΡΠΊΠ°Π·Π°Π½Π½ΡΡ
Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΊΠΎΠ² ΠΈ ΡΠ»ΡΡΡΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΡΠΎΡΠ΅ΡΡΠ° ΠΏΠ΅ΡΠ΅ΡΠ°Π±ΠΎΡΠΊΠΈ ΡΡΠΎΡΠ½ΡΡ
Π²ΠΎΠ΄. Π Ρ
ΠΎΠ΄Π΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΡΡΠΎΠ²Π΅ΡΡΠ΅Π½ΡΡΠ²ΠΎΠ²Π°Π½Π½ΡΠΉ Π°Π²ΡΠΎΡΠ°ΠΌΠΈ ΠΌΠ΅ΡΠΎΠ΄ ΡΠ΅ΡΡΠΈΡΠΈΠ·Π°ΡΠΈΠΈ Ρ ΡΠ»Π΅ΠΊΡΡΠΎΠΌΠ°Π³Π½ΠΈΡΠ½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠ΅ΠΉ ΠΏΡΠΎΡΠ΅ΡΡΠ°, ΠΊΠΎΡΠΎΡΡΠΉ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΠΏΠΎΠ²ΡΡΠΈΡΡ Π΅Π³ΠΎ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ. ΠΠ΄Π½Π°ΠΊΠΎ ΠΏΠ»ΠΎΡΠ½ΡΠ΅ ΠΈ ΡΡΠΎΠΉΠΊΠΈΠ΅ ΠΎΡΠ°Π΄ΠΊΠΈ ΡΠ΅ΡΡΠΈΡΠΈΠ·Π°ΡΠΈΠΈ, ΠΊΠΎΡΠΎΡΡΠ΅ ΡΠΎΠ΄Π΅ΡΠΆΠ°Ρ ΡΠΎΠΊΡΠΈΡΠ½ΡΠ΅ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΡ ΡΡΠΆΠ΅Π»ΡΡ
ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠ², ΡΡΠ΅Π±ΡΡΡ Π½Π°Π΄Π΅ΠΆΠ½ΠΎΠΉ ΡΡΠΈΠ»ΠΈΠ·Π°ΡΠΈΠΈ. ΠΠΎ Π΄Π°ΠΆΠ΅ ΠΏΡΠΈ Π½Π°Π΄Π»Π΅ΠΆΠ°ΡΠ΅ΠΉ ΠΎΡΠΈΡΡΠΊΠ΅ ΡΡΠΎΡΠ½ΡΡ
Π²ΠΎΠ΄ ΠΎΡ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ ΡΡΠΆΠ΅Π»ΡΡ
ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠ² ΠΎΠ½ΠΈ ΡΠΎΠ΄Π΅ΡΠΆΠ°Ρ Π±ΠΎΠ»ΡΡΠΎΠ΅ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ Π΄ΡΡΠ³ΠΈΡ
Π·Π°Π³ΡΡΠ·Π½ΠΈΡΠ΅Π»Π΅ΠΉ, ΡΡΠΎ Π΄Π΅Π»Π°Π΅Ρ Π½Π΅Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΡΠΌ ΡΠ±ΡΠΎΡ ΡΠ°ΠΊΠΎΠΉ Π²ΠΎΠ΄Ρ Π² ΠΏΡΠΈΡΠΎΠ΄Π½ΡΠ΅ Π²ΠΎΠ΄ΠΎΠ΅ΠΌΡ, Π² ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ, Π²Π²ΠΈΠ΄Ρ Π΅Π΅ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΠΎΠΉ ΡΠ΅Π»ΠΎΡΠ½ΠΎΡΡΠΈ. Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° ΡΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½Π°Ρ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΡΠ°ΠΊΠΈΡ
Π½Π΅ΠΊΠΎΠ½Π΄ΠΈΡΠΈΠΎΠ½Π½ΡΡ
ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ² Π² ΡΠ²Π΅ΡΠ΄ΠΎΠΌ ΠΈ ΠΆΠΈΠ΄ΠΊΠΎΠΌ ΡΠΎΡΡΠΎΡΠ½ΠΈΠΈ ΠΊΠ°ΠΊ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠ² ΡΡΡΠΎΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ². ΠΠ°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌΠΈ ΡΠ΅ΠΌΠ΅Π½ΡΠΈΡΡΡΡΠΈΠΌΠΈ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π°ΠΌΠΈ Ρ Π½Π°Π΄Π΅ΠΆΠ½ΠΎΠΉ ΠΈΠΌΠΌΠΎΠ±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΠ΅ΠΉ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ ΡΡΠΆΠ΅Π»ΡΡ
ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠ² ΡΠ²Π»ΡΡΡΡΡ ΡΠ΅Π»ΠΎΡΠ½ΡΠ΅ Π²ΡΠΆΡΡΠΈΠ΅ Π²Π΅ΡΠ΅ΡΡΠ²Π°. Π ΡΠ°Π±ΠΎΡΠ΅ ΠΏΠΎΠ»ΡΡΠ΅Π½Ρ ΡΠΊΡΠΏΠ»ΡΠ°ΡΠ°ΡΠΈΠΎΠ½Π½ΡΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° ΡΠ°ΠΊΠΈΡ
ΠΌΠΎΠ΄ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΡΠ΅Π»ΠΎΡΠ½ΡΡ
ΡΠ΅ΠΌΠ΅Π½ΡΠΎΠ² ΠΈ Π±Π΅ΡΠΎΠ½ΠΎΠ² Π½Π° ΠΈΡ
ΠΎΡΠ½ΠΎΠ²Π΅. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΎ Π²ΡΡΠ΅Π»Π°ΡΠΈΠ²Π°Π½ΠΈΠ΅ ΠΈΠΎΠ½ΠΎΠ² ΡΡΠΆΠ΅Π»ΡΡ
ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠ² ΠΈΠ· ΠΌΠ°ΡΡΠΈΡΡ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π° ΠΈ Π΄ΠΎΠΊΠ°Π·Π°Π½Π° ΠΈΡ
Π½Π°Π΄Π΅ΠΆΠ½Π°Ρ ΡΠΈΠΊΡΠ°ΡΠΈΡ Π² ΡΡΡΡΠΊΡΡΡΠ΅ ΡΠ΅Π»ΠΎΡΠ½ΡΡ
ΡΠ΅ΠΌΠ΅Π½ΡΠΎΠ². ΠΠ»Π°Π³ΠΎΠ΄Π°ΡΡ ΡΡΠΎΠΌΡ ΠΈΠΌΠΌΠΎΠ±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΡ ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ² Π²ΠΎΠ΄ΠΎΠΎΡΠΈΡΡΠΊΠΈ Π² ΡΠ΅Π»ΠΎΡΠ½ΡΡ
ΡΠ΅ΠΌΠ΅Π½ΡΠ°Ρ
ΠΈ Π±Π΅ΡΠΎΠ½Π°Ρ
Π½Π° ΠΈΡ
ΠΎΡΠ½ΠΎΠ²Π΅ Π½Π΅ ΡΡ
ΡΠ΄ΡΠ°Π΅Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΈΡ
ΡΠΊΡΠΏΠ»ΡΠ°ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΡΠ²ΠΎΠΉΡΡΠ² ΠΈ ΠΏΡΠΈ ΡΡΠΎΠΌ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°Π΅Ρ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π° ΡΠ°ΠΊΠΎΠΉ ΡΡΠΈΠ»ΠΈΠ·Π°ΡΠΈΠΈ ΠΎΡΡ
ΠΎΠ΄ΠΎΠ².Π ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ Π°Π½Π°Π»ΠΎΠ³ΠΈΡΠ½ΡΠΌΠΈ ΠΈΠ·Π²Π΅ΡΡΠ½ΡΠΌΠΈ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠΌΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° ΠΏΠΎΠ»Π½ΠΎΡΡΡΡ Π±Π΅Π·ΠΎΡΡ
ΠΎΠ΄Π½Π°Ρ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΠΎΡΠΈΡΡΠΊΠΈ ΠΏΡΠΎΠΌΡΡΠ»Π΅Π½Π½ΡΡ
ΡΡΠΎΠΊΠΎΠ² Π³Π°Π»ΡΠ²Π°Π½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ² ΠΏΡΠΎΠΌΡΡΠ»Π΅Π½Π½ΡΡ
ΠΏΡΠ΅Π΄ΠΏΡΠΈΡΡΠΈΠΉ.ΠΠ±'ΡΠΊΡΠΎΠΌ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Ρ ΡΡΠ΄ΠΊΡ ΡΠ° ΡΠ²Π΅ΡΠ΄Ρ Π²ΡΠ΄Ρ
ΠΎΠ΄ΠΈ, ΡΠΊΡ ΠΎΡΡΠΈΠΌΠ°Π½Ρ Π² ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΠ΅ΡΠ΅ΡΠΎΠ±ΠΊΠΈ Π²ΠΈΡΠΎΠΊΠΎΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠΎΠ²Π°Π½ΠΈΡ
ΡΡΡΡΠ½ΠΈΡ
Π²ΠΎΠ΄ ΠΏΡΠΎΠΌΠΈΡΠ»ΠΎΠ²ΠΈΡ
ΠΏΡΠ΄ΠΏΡΠΈΡΠΌΡΡΠ² ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΡΠ΅ΡΠΈΡΠΈΠ·Π°ΡΡΡ. ΠΡΠ΄ΠΎΠΌΠΎ, ΡΠΎ Π³Π°Π»ΡΠ²Π°Π½ΡΡΠ½Ρ Π²ΠΈΡΠΎΠ±Π½ΠΈΡΡΠ²Π° ΡΡΠ²ΠΎΡΡΡΡΡ Π²Π΅Π»ΠΈΠΊΡ ΠΎΠ±βΡΠΌΠΈ Π²ΠΈΡΠΎΠΊΠΎΡΠΎΠΊΡΠΈΡΠ½ΠΈΡ
Π²ΡΠ΄Ρ
ΠΎΠ΄ΡΠ², ΡΠΊΡ ΠΏΠΎΡΡΠ΅Π±ΡΡΡΡ ΠΏΠΎΠ΄Π°Π»ΡΡΠΎΡ ΠΏΠ΅ΡΠ΅ΡΠΎΠ±ΠΊΠΈ Π°Π±ΠΎ Π±Π΅Π·ΠΏΠ΅ΡΠ½ΠΎΠ³ΠΎ Π·Π°Ρ
ΠΎΡΠΎΠ½Π΅Π½Π½Ρ. ΠΠ΄Π½ΠΈΠΌ Π· Π½Π°ΠΉΠ±ΡΠ»ΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ½ΠΈΡ
ΠΌΡΡΡΡ Ρ Π·Π°ΡΡΠΎΡΡΠ²Π°Π½Π½Ρ ΡΡΠ°Π΄ΠΈΡΡΠΉΠ½ΠΈΡ
ΡΠ΅Π°Π³Π΅Π½ΡΠ½ΠΈΡ
ΠΌΠ΅ΡΠΎΠ΄ΡΠ², ΡΠΊΡ Π½Π΅ Π·Π°Π±Π΅Π·ΠΏΠ΅ΡΡΡΡΡ Π²ΠΈΡΠΎΠΊΠΈΡ
ΠΏΠΎΠΊΠ°Π·Π½ΠΈΠΊΡΠ² ΠΎΡΠΈΡΠ΅Π½ΠΎΡ Π²ΠΎΠ΄ΠΈ ΡΠ° Ρ
ΡΠΌΡΡΠ½ΠΎΡ ΡΡΡΠΉΠΊΠΎΡΡΡ Π·Π½Π°ΡΠ½ΠΎΡ ΠΊΡΠ»ΡΠΊΠΎΡΡΡ ΡΠ²Π΅ΡΠ΄ΠΎΡΠ°Π·Π½ΠΈΡ
Π²ΡΠ΄Ρ
ΠΎΠ΄ΡΠ² Π²ΠΎΠ΄ΠΎΠΎΡΠΈΡΠ΅Π½Π½Ρ.ΠΠΈΠΊΠΎΡΠΈΡΡΠ°Π½Π½Ρ ΡΠ΅ΡΠΈΡΠΈΠ·Π°ΡΡΠΉΠ½ΠΎΡ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΡΡ Π΄ΠΎΠ·Π²ΠΎΠ»ΡΡ ΡΡΡΠ½ΡΡΠΈ Π·Π°Π·Π½Π°ΡΠ΅Π½Ρ Π½Π΅Π΄ΠΎΠ»ΡΠΊΠΈ ΡΠ° ΠΏΠΎΠΊΡΠ°ΡΠΈΡΠΈ Π΅ΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡΡΡ ΠΏΡΠΎΡΠ΅ΡΡ ΠΏΠ΅ΡΠ΅ΡΠΎΠ±ΠΊΠΈ ΠΏΡΠΎΠΌΠΈΡΠ»ΠΎΠ²ΠΈΡ
ΡΡΡΡΠ½ΠΈΡ
Π²ΠΎΠ΄. Π Ρ
ΠΎΠ΄Ρ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π²ΠΈΠΊΠΎΡΠΈΡΡΠΎΠ²ΡΠ²Π°Π»ΠΈΡΡ ΡΠ΄ΠΎΡΠΊΠΎΠ½Π°Π»Π΅Π½ΠΈΠΉ Π°Π²ΡΠΎΡΠ°ΠΌΠΈ ΠΌΠ΅ΡΠΎΠ΄ ΡΠ΅ΡΠΈΡΠΈΠ·Π°ΡΡΡ ΡΠ· Π΅Π»Π΅ΠΊΡΡΠΎΠΌΠ°Π³Π½ΡΡΠ½ΠΎΡ Π°ΠΊΡΠΈΠ²Π°ΡΡΡΡ ΠΏΡΠΎΡΠ΅ΡΡ, ΡΠΎ Π΄ΠΎΠ·Π²ΠΎΠ»ΡΡ ΡΡΡΡΡΠ²ΠΎ ΠΏΡΠ΄Π²ΠΈΡΠΈΡΠΈ ΠΉΠΎΠ³ΠΎ Π΅Π½Π΅ΡΠ³ΠΎΠ΅ΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡΡΡ. ΠΡΠΎΡΠ΅ ΡΡΠ»ΡΠ½Ρ Ρ ΡΡΡΠΉΠΊΡ ΠΎΡΠ°Π΄ΠΈ ΡΠ΅ΡΠΈΡΠΈΠ·Π°ΡΡΡ, ΡΠΊΡ ΠΌΡΡΡΡΡΡ ΡΠΎΠΊΡΠΈΡΠ½Ρ ΡΠΏΠΎΠ»ΡΠΊΠΈ Π²Π°ΠΆΠΊΠΈΡ
ΠΌΠ΅ΡΠ°Π»ΡΠ², ΠΏΠΎΡΡΠ΅Π±ΡΡΡΡ Π½Π°Π΄ΡΠΉΠ½ΠΎΡ ΡΡΠΈΠ»ΡΠ·Π°ΡΡΡ. ΠΠ»Π΅ Π½Π°Π²ΡΡΡ ΠΏΡΠΈ Π½Π°Π»Π΅ΠΆΠ½ΠΎΠΌΡ ΠΎΡΠΈΡΠ΅Π½Π½Ρ ΡΡΡΡΠ½ΠΈΡ
Π²ΠΎΠ΄ Π²ΡΠ΄ ΡΠΏΠΎΠ»ΡΠΊ Π²Π°ΠΆΠΊΠΈΡ
ΠΌΠ΅ΡΠ°Π»ΡΠ², Π²ΠΎΠ½ΠΈ ΠΌΡΡΡΡΡΡ Π²Π΅Π»ΠΈΠΊΡ ΠΊΡΠ»ΡΠΊΡΡΡΡ ΡΠ½ΡΠΈΡ
Π·Π°Π±ΡΡΠ΄Π½ΡΠ²Π°ΡΡΠ², ΡΠΎ ΡΠ½Π΅ΠΌΠΎΠΆΠ»ΠΈΠ²Π»ΡΡ ΡΠΊΠΈΠ΄Π°Π½Π½Ρ ΡΠ°ΠΊΠΎΡ Π²ΠΎΠ΄ΠΈ Ρ ΠΏΡΠΈΡΠΎΠ΄Π½Ρ Π²ΠΎΠ΄ΠΎΠΉΠΌΠΈ, Π·ΠΎΠΊΡΠ΅ΠΌΠ°, ΡΠ΅ΡΠ΅Π· ΡΡ ΠΏΡΠ΄Π²ΠΈΡΠ΅Π½Ρ Π»ΡΠΆΠ½ΡΡΡΡ. Π ΠΎΠ·ΡΠΎΠ±Π»Π΅Π½ΠΎ Π΅ΠΊΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΎ Π±Π΅Π·ΠΏΠ΅ΡΠ½Π΅ Π²ΠΈΠΊΠΎΡΠΈΡΡΠ°Π½Π½Ρ ΡΠ°ΠΊΠΈΡ
Π½Π΅ΠΊΠΎΠ½Π΄ΠΈΡΡΠΉΠ½ΠΈΡ
ΠΏΡΠΎΠ΄ΡΠΊΡΡΠ² Ρ ΡΠ²Π΅ΡΠ΄ΠΎΠΌΡ ΡΠ° ΡΡΠ΄ΠΊΠΎΠΌΡ ΡΡΠ°Π½Ρ ΡΠΊ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΡΠ² Π±ΡΠ΄ΡΠ²Π΅Π»ΡΠ½ΠΈΡ
ΠΌΠ°ΡΠ΅ΡΡΠ°Π»ΡΠ². ΠΠ°ΠΉΠ±ΡΠ»ΡΡ Π΅ΡΠ΅ΠΊΡΠΈΠ²Π½ΠΈΠΌΠΈ ΡΠ΅ΠΌΠ΅Π½ΡΡΡΡΠΈΠΌΠΈ ΠΌΠ°ΡΠ΅ΡΡΠ°Π»Π°ΠΌΠΈ ΡΠ· Π½Π°Π΄ΡΠΉΠ½ΠΎΡ ΡΠΌΠΌΠΎΠ±ΡΠ»ΡΠ·Π°ΡΡΡ ΡΠΏΠΎΠ»ΡΠΊ ΠΏΡΠΎΠΌΠΈΡΠ»ΠΎΠ²ΠΈΡ
Π²ΡΠ΄Ρ
ΠΎΠ΄ΡΠ² Ρ Π»ΡΠΆΠ½Ρ Π²βΡΠΆΡΡΡ ΡΠ΅ΡΠΎΠ²ΠΈΠ½ΠΈ. Π ΡΠΎΠ±ΠΎΡΡ ΠΎΡΡΠΈΠΌΠ°Π½Ρ Π΅ΠΊΡΠΏΠ»ΡΠ°ΡΠ°ΡΡΠΉΠ½Ρ Π²Π»Π°ΡΡΠΈΠ²ΠΎΡΡΡ ΡΠ°ΠΊΠΈΡ
ΠΌΠΎΠ΄ΠΈΡΡΠΊΠΎΠ²Π°Π½ΠΈΡ
Π»ΡΠΆΠ½ΠΈΡ
ΡΠ΅ΠΌΠ΅Π½ΡΡΠ² ΡΠ° Π±Π΅ΡΠΎΠ½ΡΠ² Π½Π° ΡΡ
ΠΎΡΠ½ΠΎΠ²Ρ. ΠΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½ΠΎ Π²ΠΈΠ»ΡΠ³ΠΎΠ²ΡΠ²Π°Π½Π½Ρ ΡΠΎΠ½ΡΠ² Π²Π°ΠΆΠΊΠΈΡ
ΠΌΠ΅ΡΠ°Π»ΡΠ² ΡΠ· ΠΌΠ°ΡΡΠΈΡΡ ΠΌΠ°ΡΠ΅ΡΡΠ°Π»Ρ ΡΠ° Π΄ΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΡΡ
Π½Π°Π΄ΡΠΉΠ½Ρ ΡΡΠΊΡΠ°ΡΡΡ Ρ ΡΡΡΡΠΊΡΡΡΡ Π»ΡΠΆΠ½ΠΈΡ
ΡΠ΅ΠΌΠ΅Π½ΡΡΠ². ΠΠ°Π²Π΄ΡΠΊΠΈ ΡΡΠΎΠΌΡ ΡΠΌΠΌΠΎΠ±ΡΠ»ΡΠ·Π°ΡΡΡ ΠΏΡΠΎΠ΄ΡΠΊΡΡΠ² Π²ΠΎΠ΄ΠΎΠΎΡΠΈΡΠ΅Π½Π½Ρ Π² Π»ΡΠΆΠ½ΠΈΡ
ΡΠ΅ΠΌΠ΅Π½ΡΠ°Ρ
ΡΠ° Π±Π΅ΡΠΎΠ½Π°Ρ
Π½Π° ΡΡ
ΠΎΡΠ½ΠΎΠ²Ρ Π½Π΅ ΠΏΠΎΠ³ΡΡΡΡΡ ΠΏΠΎΠΊΠ°Π·Π½ΠΈΠΊΠΈ ΡΡ
Π΅ΠΊΡΠΏΠ»ΡΠ°ΡΠ°ΡΡΠΉΠ½ΠΈΡ
Π²Π»Π°ΡΡΠΈΠ²ΠΎΡΡΠ΅ΠΉ Ρ ΠΏΡΠΈ ΡΡΠΎΠΌΡ Π·Π°Π±Π΅Π·ΠΏΠ΅ΡΡΡ ΠΏΠ΅ΡΠ΅Π²Π°Π³ΠΈ ΡΠ°ΠΊΠΎΡ ΡΡΠΈΠ»ΡΠ·Π°ΡΡΡ Π²ΡΠ΄Ρ
ΠΎΠ΄ΡΠ².Π£ ΠΏΠΎΡΡΠ²Π½ΡΠ½Π½Ρ Π· Π°Π½Π°Π»ΠΎΠ³ΡΡΠ½ΠΈΠΌΠΈ Π²ΡΠ΄ΠΎΠΌΠΈΠΌΠΈ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΡΡΠΌΠΈ ΡΠΎΠ·ΡΠΎΠ±Π»Π΅Π½ΠΎ ΠΏΠΎΠ²Π½ΡΡΡΡ Π±Π΅Π·Π²ΡΠ΄Ρ
ΠΎΠ΄Π½Ρ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½Ρ ΠΎΡΠΈΡΡΠΊΡ ΠΏΡΠΎΠΌΠΈΡΠ»ΠΎΠ²ΠΈΡ
ΡΡΠΎΠΊΡΠ² Π³Π°Π»ΡΠ²Π°Π½ΡΡΠ½ΠΈΡ
Π²ΠΈΡΠΎΠ±Π½ΠΈΡΡΠ² ΠΏΡΠΎΠΌΠΈΡΠ»ΠΎΠ²ΠΈΡ
ΠΏΡΠ΄ΠΏΡΠΈΡΠΌΡΡΠ²
SPARC-like 1 Regulates the Terminal Phase of Radial Glia-Guided Migration in the Cerebral Cortex
Differential adhesion between migrating neurons and transient radial glial fibers enables the deployment of neurons into appropriate layers in the developing cerebral cortex. The identity of radial glial signals that regulate the termination of migration remains unclear. Here, we identified a radial glial surface antigen, SPARC (secreted protein acidic and rich in cysteine)-like 1, distributed predominantly in radial glial fibers passing through the upper strata of the cortical plate (CP) where neurons end their migration. Neuronal migration and adhesion assays indicate that SPARC-like 1 functions to terminate neuronal migration by reducing the adhesivity of neurons at the top of the CP. Cortical neurons fail to achieve appropriate positions in the absence of SPARC-like 1 function in vivo. Together, these data suggest that antiadhesive signaling via SPARC-like 1 on radial glial cell surfaces may enable neurons to recognize the end of migration in the developing cerebral cortex
γͺγ³γ¬γ―γ²γ γγ§γ¦γ²γ³ γ«γγ€ γγͺγ±γ« γ¬γ€γγ γγ€γγ γ±γ€γ·γ§γ¦ γ γ€γ : γͺγ³γ¬γ―γ²γ γγ£γ―γγ³ γγΏγ«γΊγ© γ³γγγγ³ γͺ γΈγ¬γ€ γγ·γ
The purpose of this paper is to consider the meaning of external, internal images in the process of expression on music drama. The major results of this consideration can be summarized as follows: The external image is the "form" of reality, embodiment, that is to say, something visible and audible. On the other hand, the internal image is the simbolic form of idea, imagination, visions, enviromental factor, affect (i. e. substance of consciousness, etc.), that is to say, samething invisible. And the expression in the Music Drama is itself the mental act of representing subject subsisted in emotion and reality from expression, such as singing, acting and the theatrical line, etc..ε½η«ζ
ε ±ε¦η η©Άζγη η©Άη΄θ¦ε
¬ιζ―ζ΄δΊζ₯γγ«γγι»εε
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
Background:
Children with HIV-associated tuberculosis (TB) have few antiretroviral therapy (ART) options. We aimed to evaluate the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for HIV-associated TB.
Methods:
We nested a two-period, fixed-order pharmacokinetic substudy within the open-label, multicentre, randomised, controlled, non-inferiority ODYSSEY trial at research centres in South Africa, Uganda, and Zimbabwe. Children (aged 4 weeks to <18 years) with HIV-associated TB who were receiving rifampicin and twice-daily dolutegravir were eligible for inclusion. We did a 12-h pharmacokinetic profile on rifampicin and twice-daily dolutegravir and a 24-h profile on once-daily dolutegravir. Geometric mean ratios for trough plasma concentration (Ctrough), area under the plasma concentration time curve from 0 h to 24 h after dosing (AUC0β24 h), and maximum plasma concentration (Cmax) were used to compare dolutegravir concentrations between substudy days. We assessed rifampicin Cmax on the first substudy day. All children within ODYSSEY with HIV-associated TB who received rifampicin and twice-daily dolutegravir were included in the safety analysis. We described adverse events reported from starting twice-daily dolutegravir to 30 days after returning to once-daily dolutegravir. This trial is registered with ClinicalTrials.gov (NCT02259127), EudraCT (2014β002632-14), and the ISRCTN registry (ISRCTN91737921).
Findings:
Between Sept 20, 2016, and June 28, 2021, 37 children with HIV-associated TB (median age 11Β·9 years [range 0Β·4β17Β·6], 19 [51%] were female and 18 [49%] were male, 36 [97%] in Africa and one [3%] in Thailand) received rifampicin with twice-daily dolutegravir and were included in the safety analysis. 20 (54%) of 37 children enrolled in the pharmacokinetic substudy, 14 of whom contributed at least one evaluable pharmacokinetic curve for dolutegravir, including 12 who had within-participant comparisons. Geometric mean ratios for rifampicin and twice-daily dolutegravir versus once-daily dolutegravir were 1Β·51 (90% CI 1Β·08β2Β·11) for Ctrough, 1Β·23 (0Β·99β1Β·53) for AUC0β24 h, and 0Β·94 (0Β·76β1Β·16) for Cmax. Individual dolutegravir Ctrough concentrations were higher than the 90% effective concentration (ie, 0Β·32 mg/L) in all children receiving rifampicin and twice-daily dolutegravir. Of 18 children with evaluable rifampicin concentrations, 15 (83%) had a Cmax of less than the optimal target concentration of 8 mg/L. Rifampicin geometric mean Cmax was 5Β·1 mg/L (coefficient of variation 71%). During a median follow-up of 31 weeks (IQR 30β40), 15 grade 3 or higher adverse events occurred among 11 (30%) of 37 children, ten serious adverse events occurred among eight (22%) children, including two deaths (one tuberculosis-related death, one death due to traumatic injury); no adverse events, including deaths, were considered related to dolutegravir.
Interpretation:
Twice-daily dolutegravir was shown to be safe and sufficient to overcome the rifampicin enzyme-inducing effect in children, and could provide a practical ART option for children with HIV-associated TB
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
BACKGROUND: Cohort studies in adults with HIV showed that dolutegravir was associated with neuropsychiatric adverse events and sleep problems, yet data are scarce in children and adolescents. We aimed to evaluate neuropsychiatric manifestations in children and adolescents treated with dolutegravir-based treatment versus alternative antiretroviral therapy. METHODS: This is a secondary analysis of ODYSSEY, an open-label, multicentre, randomised, non-inferiority trial, in which adolescents and children initiating first-line or second-line antiretroviral therapy were randomly assigned 1:1 to dolutegravir-based treatment or standard-of-care treatment. We assessed neuropsychiatric adverse events (reported by clinicians) and responses to the mood and sleep questionnaires (reported by the participant or their carer) in both groups. We compared the proportions of patients with neuropsychiatric adverse events (neurological, psychiatric, and total), time to first neuropsychiatric adverse event, and participant-reported responses to questionnaires capturing issues with mood, suicidal thoughts, and sleep problems. FINDINGS: Between Sept 20, 2016, and June 22, 2018, 707 participants were enrolled, of whom 345 (49%) were female and 362 (51%) were male, and 623 (88%) were Black-African. Of 707 participants, 350 (50%) were randomly assigned to dolutegravir-based antiretroviral therapy and 357 (50%) to non-dolutegravir-based standard-of-care. 311 (44%) of 707 participants started first-line antiretroviral therapy (ODYSSEY-A; 145 [92%] of 157 participants had efavirenz-based therapy in the standard-of-care group), and 396 (56%) of 707 started second-line therapy (ODYSSEY-B; 195 [98%] of 200 had protease inhibitor-based therapy in the standard-of-care group). During follow-up (median 142 weeks, IQR 124β159), 23 participants had 31 neuropsychiatric adverse events (15 in the dolutegravir group and eight in the standard-of-care group; difference in proportion of participants with β₯1 event p=0Β·13). 11 participants had one or more neurological events (six and five; p=0Β·74) and 14 participants had one or more psychiatric events (ten and four; p=0Β·097). Among 14 participants with psychiatric events, eight participants in the dolutegravir group and four in standard-of-care group had suicidal ideation or behaviour. More participants in the dolutegravir group than the standard-of-care group reported symptoms of self-harm (eight vs one; p=0Β·025), life not worth living (17 vs five; p=0Β·0091), or suicidal thoughts (13 vs none; p=0Β·0006) at one or more follow-up visits. Most reports were transient. There were no differences by treatment group in low mood or feeling sad, problems concentrating, feeling worried or feeling angry or aggressive, sleep problems, or sleep quality. INTERPRETATION: The numbers of neuropsychiatric adverse events and reported neuropsychiatric symptoms were low. However, numerically more participants had psychiatric events and reported suicidality ideation in the dolutegravir group than the standard-of-care group. These differences should be interpreted with caution in an open-label trial. Clinicians and policy makers should consider including suicidality screening of children or adolescents receiving dolutegravir
Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels
Leptin is an adipocyte-secreted hormone, the circulating levels of which correlate closely with overall adiposity. Although rare mutations in the leptin (LEP) gene are well known to cause leptin deficiency and severe obesity, no common loci regulating circulating leptin levels have been uncovered. Therefore, we performed a genome-wide association study (GWAS) of circulating leptin levels from 32,161 individuals and followed up loci reaching P <10(-6) in 19,979 additional individuals. We identify five loci robustly associated (P <5 x 10(-8)) with leptin levels in/near LEP, SLC32A1, GCKR, CCNL1 and FTO. Although the association of the FTO obesity locus with leptin levels is abolished by adjustment for BMI, associations of the four other loci are independent of adiposity. The GCKR locus was found associated with multiple metabolic traits in previous GWAS and the CCNL1 locus with birth weight. Knockdown experiments in mouse adipose tissue explants show convincing evidence for adipogenin, a regulator of adipocyte differentiation, as the novel causal gene in the SLC32A1 locus influencing leptin levels. Our findings provide novel insights into the regulation of leptin production by adipose tissue and open new avenues for examining the influence of variation in leptin levels on adiposity and metabolic health.Peer reviewe